Skip to main content
. 2021 Jan 29;8(6):2003091. doi: 10.1002/advs.202003091

Figure 8.

Figure 8

Anti‐CD38 CAR‐T cell‐mediated antitumor response in xenografted immunocompromised mice. a) NOG mice were intravenously implanted with luciferase‐transduced human CD38+ Daudi cells (1 × 106 cells). Upon successful engraftment, mice were intravenously treated with 1 × 107 mock‐T or RP02 CAR‐T cells once. Tumor load was quantified by BLI measurements. Bioluminescent images are shown per group at weekly intervals. b) Survival curves of mice receiving mock‐T or RP02 CAR‐T cells (n = 4).